Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants.
10.7499/j.issn.1008-8830.2210119
- Author:
Jing-Li YANG
1
;
Jian-Hui WANG
1
Author Information
1. Department of Neonatology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
- Publication Type:Journal Article
- Keywords:
Guideline;
Hyperbilirubinemia;
Interpretation;
Newborn infant
- MeSH:
Infant, Newborn;
Humans;
Infant;
United States;
Child;
Hyperbilirubinemia, Neonatal/therapy*;
Bilirubin;
Hyperbilirubinemia/therapy*;
Kernicterus/prevention & control*;
Risk Assessment;
Gestational Age
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(1):11-17
- CountryChina
- Language:Chinese
-
Abstract:
The American Academy of Pediatrics updated the guidelines for the management of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks in September 2022. Based on the evidence over the past 18 years, the guidelines are updated from the aspects of the prevention, risk assessment, intervention, and follow-up of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks. This article gives an interpretation of the key points in the guidelines, so as to safely reduce the risk of bilirubin encephalopathy and unnecessary intervention.
